Institutional Ownership and Shareholder Breakdown of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA)

Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) has 38% institutional ownership, indicating a significant sensitivity to institutional trading actions. The top 9 shareholders hold 51% of the business, suggesting that a good portion of institutional money invested in the company is a vote of confidence on its future. Ownership research combined with past performance data can help provide a good understanding of opportunities in a stock.

Mizuho Securities USA LLC recently purchased 542,962 shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA), valued at approximately $5.4 million, according to its latest SEC filing [1]. This acquisition represents about 1.86% of the company's total shares, signaling a significant institutional investment.

Drugs Made In America Acquisition Corp. is a blank check company based in the Cayman Islands, focusing on mergers and acquisitions. The company's latest stock performance indicates a trading volume of 878 shares, with a 1-year low of $9.95 and a 1-year high of $10.28 [1]. The stock traded up $0.03 on Thursday, reaching $10.28.

Institutional ownership of Drugs Made In America Acquisition Corp. stands at 38%, with the top 9 shareholders holding 51% of the business [1]. This high level of institutional ownership suggests a strong vote of confidence in the company's future prospects.

The acquisition by Mizuho Securities USA LLC adds to the company's institutional ownership, indicating a positive outlook among investors. However, the company's stock has not been highlighted by top analysts as a preferred investment, with MarketBeat identifying five other stocks as better buys [1].

References:

[1] https://www.marketbeat.com/instant-alerts/filing-542962-shares-in-drugs-made-in-america-acquisition-corp-nasdaqdmaa-bought-by-mizuho-securities-usa-llc-2025-08-10/